Please assess the completion status of the following clinical trial:

Trial Title: Randomized, Controlled, Double Blind Trial of Eszopiclone for Insomnia Associated With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Be between the ages of 18 to 64~* Meet DSM-IV criteria for schizophrenia or schizoaffective disorder~* Sleep difficulties at least 2x per week in the preceding month~* Be on a stable dose of antipsychotic medication~* Symptomatically stable in the last 2 months~* English speaking.~Exclusion Criteria:~* Meet criteria for current alcohol or other substance dependence~* A history of dementia, mental retardation or other neurological disorder~* Not capable of giving informed consent for participation in this study.~* Ongoing pregnancy~* Known sensitivity to zopiclone.~* Insomnia associated with medical disorders likely to impair sleep.~* Use of any medication that affects sleep/wake function (other than antipsychotic medication), within the past 2 weeks or within a time period that is less than 7 half-lives since last use of the medication.~* Lack of sleep benefit from previous adequate eszopiclone treatment~* History of clinically significant hepatic impairment.~* Subject is taking a potent cytochrome p450 3A4 inhibitor medication (ritonavir, nelfinavir, indinavir, erythromycin, clarithromycin, troleandomycin, ketoconazole, itraconazole) and is unwilling or it is clinically contraindicated to stop the medication.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Eszopiclone Group (Type: EXPERIMENTAL): Participants assigned to this arm will receive Eszopiclone 2mg each night for the first week then Eszopiclone 3mg each night for the remaining weeks.
- Placebo Group (Type: PLACEBO_COMPARATOR): Participants assigned to this arm will receive placebo (an inactive substance or a sugar pill) to be taken each night for all weeks of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).